Ambra

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Elisa Elisa

Airlangga University

Cappello

Алессандро

Universität Hamburg

Schilliro

Marchetti

Universidad Nacional de La Plata

Fabio Fabio

Università degli Studi di Enna Kore

Erin

Macaluso

United States Department of Veterans Affairs

Barco

Serena

Cooperative Institutions

Istituti di Ricovero e Cura a Carattere Scientifico

University of North Sumatra

Universität Hamburg

Universitat de Barcelona

Bandung Institute of Technology

Airlangga University

Syiah Kuala University

State University of Malang

Institut Ilmu Kesehatan Bhakti Wiyata

Universitas Almuslim

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

临床的路线和 hepatorenal 症候群的预示的因素: 回顾的单个中心的队研究

世界肝病学杂志：英文版（电子版） (2013)

Анна Licata Marcello Maida Maida Ambra

AIM: To investigate clinical and biochemical features of hepatorenal syndrome(HRS), to assess short and long- term survival evaluating potential predictors of early mortality. METHODS: Sixty-two patients with liver cirrhosis and renal failure, defined as a serum creatinine value > 1.5 mg/dL on at least two measurements within 48 h, admitted to our tertiary referral Unit from 2001 to 201, were retrospectively reviewed. Among them, 33 patients(53.2%) fulfilled the revised criteria of the International Ascites Club for the diagnosis of HRS. Twenty-eight patients were treated with combinations of terlipressin and albumin, two with dopamine and al- bumin, and three with albumin alone. No patients were suitable for liver transplantation. Complete response was defined as normalization of creatinine levels to less than 1.5 mg/dL, partial response as a decrease of at least 50% but not to less than 1.5 mg/dL, no response as no reduction in creatinine or a decrease of less 50% compared to pre-treatment values. All of the patients were followed up for at least 1 year until January 2013. RESULTS: HRS type 1 was diagnosed in 15 patients(45.5%). Hepatitis C virus infection was the primary etiology(69.6%), followed by alcohol(15.2%), and cryptogenesis(15.2%). Complete response to therapy was obtained in only 3 cases(9.1%) and partial re- sponse in 7 patients(21.2%). Median survival was 30 d(range: 10-274) without significant differences be- tween type 1 and type 2 HRS. By univariate analysis, Child-Pugh class C(P = 0.009), presence of hepatocel- lular carcinoma(P = 0.04), low serum sodium(P = 0.02), high bilirubin values(P = 0.009) and high Model for End-stage Liver Disease(MELD) score(P = 0.03) were predictive factors of 30-d mortality. By multivari- ate analysis, only serum sodium 27(OR = 18.72; P = 0.01) were independently associated with a survival of less than one month. CONCLUSION: HRS still has a poor prognosis, even when vasoactive drug therapies are extensivel

Univariate analysis

Terlipressin

Source

Cite

Citations (0)

Green Restaurant: An Ancient Touch of Chinese Herbal Food

北京周报：英文版 (2010)

Ambra Schilliro

The first time I entered the restaurant Green, inside the five-star Radegast Lake View Hotel in Chongwen District of Beijing, I was incredibly surprised. All around were red lights, a room reminiscent of the splendor of ancient China and simply delicious herbal cuisine.

Source

Cite

Citations (0)

Factors associated with HPV-DNA clearance in a cohort of HIV-positive patients: role of cART and gender

Elisa Elisa Bai Francesca Francesca Comi Laura

Introduction: We aimed to assess any factors associated with dysplasia regression and with HPV clearance in a cohort of HIV patients, with particular focus on cART and gender. Methods: Asymptomatic HIV patients of the San Paolo Infectious Disease (SPID) cohort who underwent anoscopy/ gynaecological evaluation were enrolled. Anal/cervical brushing were analyzed for: HPV-PCR detection/genotyping (HR-HPV), cytologic abnormalities (Bethesda System 2001: LSIL-HSIL). Demographics and HIV-related parameters were evaluated at baseline. Activated CD8 /CD38 lymphocytes were measured (flow citometry). Patients were examined at baseline (T0) and at 12 18 months visit (T1). HPV clearance was defined as negativisation of HPV at T1; SIL regression (SIL-R) and progression (SILP) were defined as change from HSIL/LSIL to a lower-grade/absence of dysplasia and as change from absence of HSIL/LSIL to a higher-grade dysplasia at T1, respectively. Mann Whitney test, Chi-square test and multivariate logistic regression were used. Results: A total of 189 patients were examined, 60 (32%) were women. One hundred fifty patients (79%) were HPV , 113 (75%) harboured HR-HPV; 103 (68%) showed LSIL/HSIL at T0 (32% of women and 65% of men) (all were HPV-positive). No differences in demographics and HIV-related markers were found between patients with SIL-P (33, 41%) and patients with SIL-R (47, 59%). HPV patients who cleared HPV (28, 18%) were found to be more frequently female, heterosexual infected, more frequently on cART and with lower Log10 HIV-RNA and lower levels of CD8 /CD38 % compared with HPV persistence group (Table 1). No differences in PI exposure were found between the two groups (p .08). Interestingly, also when only HR-HPV were considered, clearance was associated with exposure to cART (naive 4%, vs cART 86%, p .048). In multivariate analysis, heterosexuals (AOR 5.123, 95% CI 1.5 17.5 vs homosexuals) were independently associated to HPV clearance, whereas CD8 / CD38 % (AOR 0.44, 95% CI 0.65 1.01 for each % more) were predictive of HPV persistence. Conclusions: Close follow-up of HPV and SIL should be promoted particularly in men and in untreated individuals. We cannot exclude behavioural variables linked to risky sex and reinfection.

Cart

Concordance

Source

Cite

Citations (0)

Ambra (Dominique d'). L'objet de la fonction juridictionnelle, dire le droit et trancher les litiges, thèse de doctorat, droit pénal, Strasbourg 3, 1991, dact., 438 f°; Paris, LGDJ, 1994, 339 p.

Ambra

Source

Cite

Citations (0)

El enfrentamiento caballeresco en el Don Quijote: análisis histórico-comparativo.

Topran Cutin Ambra

Source

Cite

Citations (0)

Ambra (Dominique d'). Règlement amiable, juridiction volontaire et volonté des parties, in Le rôle de la volonté dans les actes juridiques. Études à la mémoire du Professeur Alfred Rieg, Bruxelles, Bruylant, 2000, p. 223-250.

Ambra

Source

Cite

Citations (0)

Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients

世界胃肠病学杂志：英文版（电子版） (2013)

Aléssio Provenzani Andrew Santeusanio Erin

The introduction of tacrolimus in clinical practice has improved patient survival after organ transplant.However,despite the long use of tacrolimus in clinical practice,the best way to use this agent is still a matter of intense debate.The start of the genomic era has generated new research areas,such as pharmacogenetics,which studies the variability of drug response in relation to the genetic factors involved in the processes responsible for the pharmacokinetics and/or the action mechanism of a drug in the body.This variability seems to be correlated with the presence of genetic polymorphisms.Genotyping is an attractive option especially for the initiation of the dosing of tacrolimus;also,unlike phenotypic tests,the genotype is a stable characteristic that needs to be determined only once for any given gene.However,prospective clinical studies must show that genotype determination before transplantation allows for better use of a given drug and improves the safety and clinical efficacy of that medication.At present,research has been able to reliably show that the CYP3A5 genotype,but not the CYP3A4 or ABCB1 ones,can modify the pharmacokinetics of tacrolimus.However,it has not been possible to incontrovertibly show that the corresponding changes in the pharmacokinetic profile are linked with different patient outcomes regarding tacrolimus efficacy and toxicity.For these reasons,pharmacogenetics and individualized medicine remain a fascinating area for further study and may ultimately become the face of future medical practice and drug dosing.

Therapeutic Drug Monitoring

Clinical Pharmacology

Personalized Medicine

Pharmacogenomics

Source

Cite

Citations (0)